by The Monovaccine (Epstein – Barr virus) Market consists of vaccines developed specifically for Epstein – Barr virus or human herpesvirus 4. Epstein – Barr virus is considered one of the most common human viruses that infects over 90% of adults worldwide. Monovaccines target Epstein – Barr virus and help develop immunity against infectious mononucleosis or glandular fever disease. While most infections are asymptomatic, they can result in infectious mononucleosis in adolescents and young adults. Monovaccines offer protection againstactive infection and are viewed as an important tool in reducing Epstein – Barr virus transmission.
The Global Monovaccine (Epstein – Barr virus) Market is estimated to be valued at US$ 12.01 Tn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Monovaccine (Epstein – Barr virus) Market include Kimberly-Clark, 3M Company, uvex group, The Gerson Company, Kowa Company Ltd., Moldex-Metric Inc., Bunzl PLC (SAS Safety Corp.), and Honeywell International Inc., among others. These players are engaged in new vaccine development and licensing efforts to address the unmet need of an Epstein – Barr virus vaccine.
The growing incidence of infectious mononucleosis and rising Epstein-Barr virus infection rates, especially in developing nations are driving the Monovaccine (Epstein – Barr virus) Market Demand. As per WHO, over 200 million new Epstein-Barr virus infections occur annually worldwide. A safe and effective monovaccine can help prevent a major public health burden.
Leading manufacturers are expanding their geographical presence across global markets to improve access to monovaccines. Partnerships with local pharma companies and contract manufacturing deals allow greater production scale and supply chain optimization. Regulatory approvals in new regions will further aid the global expansion of the monovaccine market over the coming years.
Market key trends
One of the key trends in the Monovaccine (Epstein-Barr virus) Market is the shift towards viral subunit vaccines. Early attempts involved live attenuated or inactivated whole virus vaccine approaches but they faced safety issues. Newer technologies focused on developing subunit vaccines containing specific viral proteins like glycoprotein that trigger strong immune response with good tolerability. This trend allows targeted vaccination against Epstein-Barr virus and reduces adverse reactions associated with traditional vaccine formats. Over the forecast period, viral subunit vaccines using viral envelope proteins are projected to gain greater demand.
Porter’s Analysis
Threat of new entrants: Low developmental and regulatory costs reduces threat.
Bargaining power of buyers: Large customer base limits individual buyer’s influence.
Bargaining power of suppliers: Limited substitutes increases supplier’s bargaining power.
Threat of new substitutes: Vaccine for other viruses pose threat of substitution.
Competitive rivalry: Strong scientific focus on vaccines keeps competition high.
The geographical region where the monovaccine (Epstein – Barr virus) market value is most concentrated is North America. The United States and Canada account for over 50% of global market value currently due to high demand, robust healthcare infrastructure, and availability of advanced treatment options.
The fastest growing region for the monovaccine (Epstein – Barr virus) market is Asia Pacific. Countries like China, Japan, and South Korea are expected to see strong growth in demand for the Epstein – Barr virus vaccine due to improving economic conditions, expansions in healthcare coverage, and rising medical tourism in the region. Rising awareness about viral diseases and their prevention is also fueling the market in Asia Pacific.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Money Singh
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. LinkedIn Profile
